Comparison of cytokine production in mice inoculated with messenger RNA vaccines BNT162b2 and mRNA-1273

被引:6
|
作者
Nakayama, Tetsuo [1 ,3 ]
Sawada, Akihito [1 ]
Ito, Takeshi [1 ,2 ]
机构
[1] Omura Satoshi Mem Inst, Lab Viral Infect, Tokyo, Japan
[2] Kitasato Univ Hosp, Dept Pediat, Sagamihara, Kanagawa, Japan
[3] Omura Satoshi Mem Inst, Lab Viral Infect, Minato Ku, Shirokane 5-9-1, Tokyo 1088641, Japan
关键词
adverse events; inflammatory cytokine; mRNA vaccine; Th1; Th2; cytokine; IMMUNIZATION; IMMUNOGENICITY; MYOCARDITIS; ZOSTER;
D O I
10.1111/1348-0421.13043
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Two messenger RNA (mRNA) vaccines of BNT162b2 and mRNA-1273 were licensed. The most common adverse event is regional pain at the injection site in 80%. As systemic reactions, fatigue and headache were noted in 40%-60% and febrile illness in 10%-40% of the recipients. To investigate the mechanism of adverse events, cytokine profiles were investigated in mice. Muscle tissue and serum samples were obtained on days 0, 1, 3, 5, and 7, and at 2 and 4 weeks after the first dose. The second dose was given 4 weeks after the first dose and samples were obtained. After inoculation with 0.1 mL of mRNA-1273, IFN-gamma and IL-2 were detected in muscle tissues and serum samples on day 1 of the second doses, and similar profiles were observed for IL-4, IL-5, and IL-12 production. mRNA-1273 induced higher levels of Th1 and Th2 cytokines. TNF-alpha was induced in muscle tissues on day 1 of the first dose and enhanced on day 1 of the second dose after inoculation with BNT162b2 and mRNA-1273. IL-6 was also detected in muscle tissue on day 1 of the first dose, but it decreased after day 3, and enhanced production was demonstrated on day 1 of the second dose. Granulocyte colony-stimulating factor in muscle tissues showed a similar profile. The induction of inflammatory cytokines in the mouse model is related to the cause of adverse events in humans, with a higher incidence of adverse events after the second dose.
引用
收藏
页码:120 / 128
页数:9
相关论文
共 50 条
  • [1] Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
    Abu-Raddad, Laith J.
    Chemaitelly, Hiam
    Bertollini, Roberto
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (08): : 799 - 800
  • [2] Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
    Zhang, Chenyang
    Yin, Guosheng
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (19): : 1818 - 1819
  • [3] Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in US Veterans
    Dickerman, Barbra A.
    Gerlovin, Hanna
    Madenci, Arin L.
    Kurgansky, Katherine E.
    Ferolito, Brian R.
    Muniz, Michael J. Figueroa
    Gagnon, David R.
    Gaziano, J. Michael
    Cho, Kelly
    Casas, Juan P.
    Hernan, Miguel A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (02): : 105 - 115
  • [4] Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273
    Teo, Shyh Poh
    JOURNAL OF PHARMACY PRACTICE, 2022, 35 (06) : 947 - 951
  • [5] Myocarditis After BNT162b2 and mRNA-1273 Vaccination
    Larson, Kathryn F.
    Ammirati, Enrico
    Adler, Eric D.
    Cooper, Leslie T., Jr.
    Hong, Kimberly N.
    Saponara, Gianluigi
    Couri, Daniel
    Cereda, Alberto
    Procopio, Antonio
    Cavalotti, Cristina
    Oliva, Fabrizio
    Sanna, Tommaso
    Ciconte, Vincenzo Antonio
    Onyango, George
    Holmes, David R.
    Borgeson, Daniel D.
    CIRCULATION, 2021, 144 (06) : 506 - 508
  • [6] Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines REPLY
    Thompson, Mark G.
    Grant, Lauren
    Meece, Jennifer
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (19): : 1819 - 1821
  • [7] Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
    Thompson, Mark G.
    Burgess, Jefferey L.
    Naleway, Allison L.
    Tyner, Harmony
    Yoon, Sarang K.
    Meece, Jennifer
    Olsho, Lauren E. W.
    Caban-Martinez, Alberto J.
    Fowlkes, Ashley L.
    Lutrick, Karen
    Groom, Holly C.
    Dunnigan, Kayan
    Odean, Marilyn J.
    Hegmann, Kurt
    Stefanski, Elisha
    Edwards, Laura J.
    Schaefer-Solle, Natasha
    Grant, Lauren
    Ellingson, Katherine
    Kuntz, Jennifer L.
    Zunie, Tnelda
    Thiese, Matthew S.
    Ivacic, Lynn
    Wesley, Meredith G.
    Mayo Lamberte, Julie
    Sun, Xiaoxiao
    Smith, Michael E.
    Phillips, Andrew L.
    Groover, Kimberly D.
    Yoo, Young M.
    Gerald, Joseph
    Brown, Rachel T.
    Herring, Meghan K.
    Joseph, Gregory
    Beitel, Shawn
    Morrill, Tyler C.
    Mak, Josephine
    Rivers, Patrick
    Poe, Brandon P.
    Lynch, Brian
    Zhou, Yingtao
    Zhang, Jing
    Kelleher, Anna
    Li, Yan
    Dickerson, Monica
    Hanson, Erika
    Guenther, Kyley
    Tong, Suxiang
    Bateman, Allen
    Reisdorf, Erik
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (04): : 320 - 329
  • [8] Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
    Kitagawa, Hiroki
    Kaiki, Yuki
    Sugiyama, Aya
    Nagashima, Shintaro
    Kurisu, Akemi
    Nomura, Toshihito
    Omori, Keitaro
    Akita, Tomoyuki
    Shigemoto, Norifumi
    Tanaka, Junko
    Ohge, Hiroki
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2022, 28 (04) : 576 - 581
  • [9] Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans
    Dickerman, Barbra A.
    Madenci, Arin L.
    Gerlovin, Hanna
    Kurgansky, Katherine E.
    Wise, Jessica K.
    Figueroa Muniz, Michael J.
    Ferolito, Brian R.
    Gagnon, David R.
    Gaziano, J. Michael
    Cho, Kelly
    Casas, Juan P.
    Hernan, Miguel A.
    JAMA INTERNAL MEDICINE, 2022, 182 (07) : 739 - 746
  • [10] Cutaneous reactions due to Pfizer's BNT162b2 mRNA and Moderna's mRNA-1273 vaccines
    Oulee, A.
    Salem, S.
    Yahia, R.
    Yang, K.
    Garcia, D.
    Holmes, A.
    Furukawa, B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (05) : E332 - E334